AI
Monday, September 20, 2010 2:57:22 PM
the way I see it other companies will have to do biosimilars (run trials to get their products approved) whereas they can probably get away with biogeneric because they may not need trials.
that would be a huge differenciation.
Thanks that is fascinating.
It also makes sense. IF a company can completely characterize and accurately control manufacturing, then trials are not necessary. Admittedly, that is a BIG IF. But if any company can do this, MNTA is it. Yes, I'm long.
ij
There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
